Literature DB >> 22350482

Surgical inflammation induces hepcidin production after abdominal surgery.

Kyung Hwa Park1, Tokihiko Sawada, Takayuki Kosuge, Junji Kita, Mitsugi Shimoda, Naohisa Tomosugi, Keiichi Kubota.   

Abstract

BACKGROUND: Hepcidin, a key regulator of iron homeostasis, is also a marker of acute inflammation. In the present study we investigated the changes in the serum hepcidin level and correlations between hepcidin and other markers of acute inflammation during the perioperative period in patients after abdominal surgery.
METHODS: Serum hepcidin, hemoglobin (Hb), hematocrit (Ht), white blood cell (WBC) count, frequency of neutrophils, and C-reactive protein (CRP) were measured preoperatively (Pre), and on postoperative days (POD) 1, 3, 7, and 14.
RESULTS: In patients undergoing gastrectomy, the median levels of hepcidin preoperatively and on POD 1, 3, 7, and 14 were 6.5, 53.1, 31.7, 15.6, and 4.0 ng/dl, respectively (p < 0.0001). The corresponding levels in colectomy patients were 8.5, 78.3, 60.1, 49.7, and 8.4 ng/dl, respectively (p = 0.0002); those in hepatectomy patients were 6.6, 16.3, 3.5, 13.4, and 3.4 ng/dl, respectively (p = 0.0022); and those in patients undergoing surgery for diffuse peritonitis were 24.8, 50.1, 43.1, 31.2, and 31.7 ng/dl, respectively (p = 0.4933). There were no significant decreases in Hb and Ht in the patients undergoing gastrectomy, colectomy, or surgery for diffuse peritonitis. The level of hepcidin was significantly correlated with the WBC count, frequency of neutrophils, and CRP level during the perioperative period for all four types of operation.
CONCLUSIONS: Like other inflammatory markers, an increase in the level of hepcidin (i.e., a hepcidin storm) occurs in the acute phase after gastrectomy, colectomy, hepatectomy, and surgery for diffuse peritonitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350482     DOI: 10.1007/s00268-012-1473-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

Review 1.  Anemia of chronic disease.

Authors:  Guenter Weiss; Lawrence T Goodnough
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

2.  Hepcidin activation during inflammation: make it STAT.

Authors:  Robert E Fleming
Journal:  Gastroenterology       Date:  2007-01       Impact factor: 22.682

3.  Hepcidin assays: ironing out some details.

Authors:  Jolanta Malyszko
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 8.237

4.  Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.

Authors:  Erwin Kemna; Peter Pickkers; Elizabeta Nemeth; Hans van der Hoeven; Dorine Swinkels
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

5.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

Review 6.  Hepcidin and disorders of iron metabolism.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 7.  Iron sequestration and anemia of inflammation.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Semin Hematol       Date:  2009-10       Impact factor: 3.851

8.  Immunoassay for human serum hepcidin.

Authors:  Tomas Ganz; Gordana Olbina; Domenico Girelli; Elizabeta Nemeth; Mark Westerman
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

9.  Nutritional markers following duodenal switch for morbid obesity.

Authors:  Robert A Rabkin; John M Rabkin; Barbara Metcalf; Myra Lazo; Michael Rossi; Lee B Lehman-Becker
Journal:  Obes Surg       Date:  2004-01       Impact factor: 4.129

10.  STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo.

Authors:  Antonello Pietrangelo; Uta Dierssen; Linda Valli; Cinzia Garuti; Agrani Rump; Elena Corradini; Matthias Ernst; Christian Klein; Christian Trautwein
Journal:  Gastroenterology       Date:  2006-10-17       Impact factor: 22.682

View more
  7 in total

1.  Hepcidin, soluble transferrin receptor and IL-6 levels in obese children and adolescents with and without type 2 diabetes mellitus/impaired glucose tolerance and their association with obstructive sleep apnea.

Authors:  S Shalitin; V Deutsch; R Tauman
Journal:  J Endocrinol Invest       Date:  2018-01-05       Impact factor: 4.256

2.  Applied value of monitoring serum hepcidin in differential diagnosis of infection versus tumor fevers.

Authors:  Ling Li; Jiang-Guo Zhang; Man-Zhi Zhao; Zhu-Hua Wu; Jian-Xin Song
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-04-11

Review 3.  The utility of iron chelators in the management of inflammatory disorders.

Authors:  C Lehmann; S Islam; S Jarosch; J Zhou; D Hoskin; A Greenshields; N Al-Banna; N Sharawy; A Sczcesniak; M Kelly; K Wafa; W Cheliak; B Holbein
Journal:  Mediators Inflamm       Date:  2015-03-23       Impact factor: 4.711

4.  Association of serum hepcidin levels with the presence and severity of obstructive sleep apnea syndrome.

Authors:  Yu Liu; Zhengang Yu; Defeng Hua; Yan Chen; Shiliang Zheng; Leqiang Wang
Journal:  Med Sci Monit       Date:  2015-01-02

5.  Serum hepcidin levels are associated with obesity but not liver disease.

Authors:  Raj Vuppalanchi; Jason S Troutt; Robert J Konrad; Marwan Ghabril; Romil Saxena; Lauren N Bell; Kris V Kowdley; Naga Chalasani
Journal:  Obesity (Silver Spring)       Date:  2013-12-17       Impact factor: 5.002

Review 6.  Hepcidin and iron homeostasis during pregnancy.

Authors:  Mary Dawn Koenig; Lisa Tussing-Humphreys; Jessica Day; Brooke Cadwell; Elizabeta Nemeth
Journal:  Nutrients       Date:  2014-08-04       Impact factor: 5.717

7.  Hepcidin, Serum Iron, and Transferrin Saturation in Full-Term and Premature Infants during the First Month of Life: A State-of-the-Art Review of Existing Evidence in Humans.

Authors:  James H Cross; Andrew M Prentice; Carla Cerami
Journal:  Curr Dev Nutr       Date:  2020-06-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.